
- /
- Supported exchanges
- / US
- / APLS.NASDAQ
Apellis Pharmaceuticals Inc (APLS NASDAQ) stock market data APIs
Apellis Pharmaceuticals Inc Financial Data Overview
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Apellis Pharmaceuticals Inc data using free add-ons & libraries
Get Apellis Pharmaceuticals Inc Fundamental Data
Apellis Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 781 M
- EBITDA: -163 182 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-25
- EPS/Forecast: -0.4019
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Apellis Pharmaceuticals Inc News

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst Last week, Apellis Pharmaceuticals Inc (NASDAQ:APLS) reported a fourth-quarter earnings loss of 29 cents per share, ...


Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues
Apellis Pharmaceuticals APLS reported fourth-quarter 2024 loss of 29 cents per share, narrower than the Zacks Consensus Estimate of a loss of 39 cents. The company had incurred a loss of 73 cents in t...

Apellis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations
Apellis Pharmaceuticals (NASDAQ:APLS) Full Year 2024 Results Key Financial Results Revenue: US$781.4m (up 97% from FY 2023). Net loss: US$197.9m (loss narrowed by 63% from FY 2023). US$0.80 loss per...

Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...
Total Revenue (Q4 2024): Approximately $213 million. SYFOVRE Revenue (Q4 2024): $168 million in US net product revenue. EMPAVELI Revenue (Q4 2024): $23 million in US net product revenue. Total Revenue...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.